Sacituzumab govitecan: Additional Ph I/II IMMU-132-01 data

Data from a cohort of 85 evaluable patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) in the open-label Phase I/II IMMU-132-01 trial showed that sacituzumab govitecan on days 1 and

Read the full 328 word article

User Sign In